Sun Pharmaceutical Industries announces Jayashree Satagopan as incoming CFO
Gujarat: Sun Pharmaceutical Industries Ltd. has announced the appointment of Jayashree Satagopan as its new Chief Financial Officer (CFO) and Key Managerial Personnel, effective July 1, 2025.
Her appointment comes as part of a planned leadership transition following the upcoming superannuation of current EVP - Finance & Accounts and Chief Financial Officer, C.S. Muralidharan, who is set to superannuate on July 1, 2025.
Satagopan, a finance leader, would join the company on May 9, 2025, as Executive Vice President - Finance & Accounts and CFO (Designate), and shall assume the position of Chief Financial Officer effective from 01 July 2025.
"Muralidharan has held the role of EVP - Finance & Accounts and CFO at Sun Pharma. He has played a significant role in Sun Pharma’s growth trajectory and strengthening governance mechanisms. Specifically, he made vital contributions in aligning business objectives with finance, Sun Pharma’s acquisitions and subsequent integration, improving transparency and reporting timelines and achieving higher productivity in finance through transformation. He also played an important role in our sustainability journey in the areas of laying out objectives, reporting, and coordination.," the Company added.
Jayashree brings over 30 years of experience in managing multiple portfolios, cutting across various geographies, in diverse sectors such as agri-solutions, healthcare, manufacturing, and automotive. In her last role, she was associated with Coromandel International Ltd., part of the Murugappa group, as President Corporate and Chief Financial Officer. She was also associated with PI Industries, International Paper Company, GE Healthcare, Ford India, and Ashok Leyland.
Jayashree is a Commerce Graduate from the University of Madras, and holds professional qualifications - Chartered Accountant (CA), Cost and Management Accountant (CMA), and Company Secretary (CS).
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
